Abstract

In vitro Safety Assays with Human Derived Cardiomyocytes…. .…Bridging the Translational Gap?

Gary Gintant, Research Fellow, Abbvie

Clever biological and engineering endeavors are providing numerous novel opportunities to address cardiac safety issues of drug candidates with the intent of bridging the “translational gap” between preclinical and clinical studies.  These efforts involve both “generalized” and patient-specific cardiac preparations. The utility of such studies depend not only on the evolving preparations, but also on the appropriate questions and interpretations, both representing challenges for future efforts.